


Crisnatol mesylate

Cat. No.:	HY-108999
CAS No.:	96389-69-4
Molecular Formula:	C ₂₄ H ₂₇ NO ₅ S
Molecular Weight:	441.54
Target:	DNA/RNA Synthesis
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Crisnatol (BWA770U) mesylate is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol mesylate shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts ^{[1][2][3]} .								
In Vitro	<p>Caution: Product has not been fully validated for medical applications. For research use only. Crisnatol (1.3 µg/mL; 24-72 h) mesylate inhibits the replication of HepG2 cells, decreases cell viability by 35%^[2]. <small>Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com</small> MCE has not independently confirmed the accuracy of these methods. They are for reference only. <small>Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA</small></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HepG2 cells</td> </tr> <tr> <td>Concentration:</td> <td>1.3 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours, 48 hours, 72 hours, and 126 hours</td> </tr> <tr> <td>Result:</td> <td>Inhibited cell viability at 48 hr.</td> </tr> </table>	Cell Line:	HepG2 cells	Concentration:	1.3 µg/mL	Incubation Time:	24 hours, 48 hours, 72 hours, and 126 hours	Result:	Inhibited cell viability at 48 hr.
Cell Line:	HepG2 cells								
Concentration:	1.3 µg/mL								
Incubation Time:	24 hours, 48 hours, 72 hours, and 126 hours								
Result:	Inhibited cell viability at 48 hr.								
In Vivo	<p>Crisnatol (25 mg/kg; p.o.; single dose) mesylate shows oral activity and shows stable metabolite profile extract of rat feces by autoradiography^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								

REFERENCES

- [1]. Adams DJ. In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator. *Cancer Res.* 1989 Dec 1;49(23):6615-20.
- [2]. Patel DK, et al. Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites. *Biochem Pharmacol.* 1991 Jul 5;42(2):337-46.
- [3]. Patel DK, et al. Disposition, metabolism, and excretion of the anticancer agent crisnatol in the rat. *Drug Metab Dispos.* 1991 Mar-Apr;19(2):491-7.